MBS, most bothersome symptom.
*Study 303 is 1 of 3 Phase III trials with VYDURA or a 75 mg rimegepant tablet formulation bioequivalent to VYDURA in acute migraine treatment. For information on Studies 301 and 302, see the SmPC.^1,3
†Participants who had not had an attack of moderate or severe pain intensity within 45 days of randomisation were instructed to return unused study medication and the eDiary to the study centre and complete all end-of-study procedures.²

MMDs, monthly migraine days.
^‡This study evaluated a rimegepant 75 mg tablet formulation bioequivalent to VYDURA.^3,4
§78 (21%) VYDURA-treated^‡ patients and 95 (26%) placebo-treated patients had a history of chronic migraine, as assessed by the site PI according to the International Classification of Headache Disorders-3 criteria.^4
||Permitted rescue medications during the 12-week double-blind treatment phase included triptans, non-steroidal anti-inflammatory drugs, paracetamol up to 1000 mg/day for a maximum of 2 consecutive days (including a fixed combination containing paracetamol 250 mg, aspirin 250 mg, and caffeine 65 mg), baclofen, antiemetics, and muscle relaxants. VYDURA^‡ was not permitted as a rescue medication.^4
¶This is the number of patients who were randomised and took at least one dose of VYDURA.⁵